| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10137595 | Life Sciences | 2018 | 43 Pages |
Abstract
Our findings suggest that gefitinib protects myocardial damage in DbCM via balancing oxidant-antioxidant system, decreased collagen deposition as well as improved CKMB, BNP, cTroponinI and SERCA2a/NCX-1. Thereby, it indicated that gefitinib may be a potential therapeutic drug for treating DbCM.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Sadia Shah, Md. Sayeed Akhtar, Md.Quamrul. Hassan, Mohd. Akhtar, Yam Nath Paudel, Abul Kalam Najmi,